Edmund K. Bartlett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Edmund K. Bartlett has a total of 374 co-authors. Here are the top co-authors by number of shared publications:
- Ciara M. Kelly
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
48 shared publications - Evan Rosenbaum
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
48 shared publications - Jason E. Chan
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
47 shared publications - Mark Andrew Dickson
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
47 shared publications - Ping Chi
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
47 shared publications - Sandra P. D’ Angelo
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
47 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 247
Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience
- 2 September 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 247
Open AccessNatural history and treatment outcomes in aggressive angiomyxoma: A single institution experience
- 19 July 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (4) , 574-583
Neoadjuvant Immune Therapy in Patients With Melanoma: Response and Toxicity in a Non‐Clinical Trial Setting
Background: Neoadjuvant therapy with immune checkpoint inhibitors (ICIs) is increasingly used in advanced or recurrent melanoma based on outcomes observed in clinical trials. The efficacy and toxicity of this in a real‐world setting remain unclear. Study Design: We conducted a retrospective review of adults with cutaneous melanoma who received neoadjuvant ICI as first line therapy at our institution between 2019 and 2024. Patients had advanced melanoma that was surgically resectable and treated with neoadjuvant intent. The primary outcome was pathological response, with a secondary outcome of immune‐related toxicity. Results: In total, 81 patients were identified. The median age was 64 (range: 21–86). There were 48 males. Most patients received 2 cycles ( n = 53) prior to resection (range: 1–7 cycles). Dual ICI was the most common approach ( n = 62). Disease stage ranged from IIC to IV, with 57% IIIC. Half were pathologic non‐responders ( n = 41). Pathologic complete response (pCR) was seen in 25% ( n = 20), near‐pCR in 2% ( n = 2) and partial PR in 10% ( n = 8). Ten (12%) patients had a discrepant PR between two or more resected sites. Immune related adverse events were observed in 34 (42%) patients; 21 (26%) grade 1–2, and 13 (16%) grade 3–4. Overall survival trended towards significance ( p = 0.07) for those with mPR. Conclusions: Non‐trial use of neoadjuvant ICI therapy is associated with a less favourable pathological response than reported in clinical trials and similar risks of toxicity.
- 19 July 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (4) , 574-583
Neoadjuvant Immune Therapy in Patients With Melanoma: Response and Toxicity in a Non‐Clinical Trial Setting
Background: Neoadjuvant therapy with immune checkpoint inhibitors (ICIs) is increasingly used in advanced or recurrent melanoma based on outcomes observed in clinical trials. The efficacy and toxicity of this in a real‐world setting remain unclear. Study Design: We conducted a retrospective review of adults with cutaneous melanoma who received neoadjuvant ICI as first line therapy at our institution between 2019 and 2024. Patients had advanced melanoma that was surgically resectable and treated with neoadjuvant intent. The primary outcome was pathological response, with a secondary outcome of immune‐related toxicity. Results: In total, 81 patients were identified. The median age was 64 (range: 21–86). There were 48 males. Most patients received 2 cycles ( n = 53) prior to resection (range: 1–7 cycles). Dual ICI was the most common approach ( n = 62). Disease stage ranged from IIC to IV, with 57% IIIC. Half were pathologic non‐responders ( n = 41). Pathologic complete response (pCR) was seen in 25% ( n = 20), near‐pCR in 2% ( n = 2) and partial PR in 10% ( n = 8). Ten (12%) patients had a discrepant PR between two or more resected sites. Immune related adverse events were observed in 34 (42%) patients; 21 (26%) grade 1–2, and 13 (16%) grade 3–4. Overall survival trended towards significance ( p = 0.07) for those with mPR. Conclusions: Non‐trial use of neoadjuvant ICI therapy is associated with a less favourable pathological response than reported in clinical trials and similar risks of toxicity.
- 4 June 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 6927-6929
Neoadjuvant PD-1 Blockade in Surgically Resectable Desmoplastic Melanoma: Cohort A of the Phase 2 SWOG S1512 Trial
- 4 June 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (8) , 6927-6929
Neoadjuvant PD-1 Blockade in Surgically Resectable Desmoplastic Melanoma: Cohort A of the Phase 2 SWOG S1512 Trial
- 8 May 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (7) , 5923-5925
Perspective Editorial: Assessment of Survival Benefit from Sentinel Node Biopsy for Melanoma: A Systematic Review and Meta-analysis
- 8 May 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (7) , 5923-5925
Perspective Editorial: Assessment of Survival Benefit from Sentinel Node Biopsy for Melanoma: A Systematic Review and Meta-analysis
- 25 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (7) , 6691-6699
Outcomes of Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma
Merkel cell carcinoma (MCC) is a rare, cutaneous malignancy with a propensity for nodal metastasis, for which prognostic factors remain poorly characterize
- 25 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (7) , 6691-6699
Outcomes of Patients Undergoing Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma
Merkel cell carcinoma (MCC) is a rare, cutaneous malignancy with a propensity for nodal metastasis, for which prognostic factors remain poorly characterize
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 3 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Normalized Kynurenine Concentrate Over Time
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 3 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Normalized Kynurenine Concentrate Over Time
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Normalized Tryptophan Concentrate Over Time
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Normalized Tryptophan Concentrate Over Time
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Representativeness of study participants.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Representativeness of study participants.